Streetbeat News

Price Targets

BZH

Wedbush analyst Jay McCanless maintains a Neutral rating on Beazer Homes USA (BZH) and raises the price target from $32 to $33.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:18 pm

DECK

Wedbush analyst Tom Nikic has maintained an Outperform rating on Deckers Outdoor (NYSE:DECK) and increased the price target from $825 to $895.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:16 pm

ALGM

Needham analyst Quinn Bolton maintains a Buy rating on Allegro Microsystems (NASDAQ:ALGM) but lowers the price target from $44 to $40.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:10 pm

CTVA

Barclays analyst Benjamin Theurer has maintained an Equal-Weight rating on Corteva (NYSE:CTVA) and increased the price target from $50 to $55.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:09 pm

RNXT

Alliance Global Partners analyst Scott Henry initiated coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and set a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:04 pm

GPN

Analysts have mixed views on Global Payments (NYSE:GPN), with ratings ranging from bullish to bearish. The average 12-month price target for GPN has increased to $150.86, up 10.28% from the previous target. The company shows strong profitability with a net margin of 14.62% but lags in ROE and ROA compared to industry benchmarks. Global Payments's market cap is below the industry average, indicating it's smaller than peers. The company's debt-to-equity ratio is healthy at 0.77.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

COLL

Analyst evaluations of Collegium Pharmaceutical (NASDAQ:COLL) over the last three months show diverse outlooks, with a recent shift towards a more bullish sentiment. The average 12-month price target has increased to $38.5, up from $32.33, indicating a 19.08% rise. Analysts from Needham, Truist Securities, and Jefferies have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Collegium Pharmaceutical's financial indicators such as revenue growth, net margin, ROE, and ROA outperform industry averages, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

CLFD

Clearfield (NASDAQ:CLFD) has received mixed analyst ratings over the past three months, with a recent negative shift in sentiment as evidenced by a decrease in the average price target by 8.78% to $40.75. The company faces challenges in revenue growth, with a significant decline of -47.72% as of September 30, 2023, but shows strong profitability with a net margin of 5.43%. Its debt management is solid, with a low debt-to-equity ratio of 0.07, although it has a below-average ROE of 0.86%.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

CMS

CMS Energy (NYSE:CMS) received mixed analyst ratings with an updated average 12-month price target of $63.17, indicating a 5.28% increase from the previous target. Analysts from firms like Guggenheim, Barclays, and JP Morgan adjusted their ratings and price targets, reflecting a generally positive outlook. Despite facing revenue challenges with a -17.34% decline over 3 months, CMS Energy showcases strong profitability with notable net margin and ROE figures. However, its high debt-to-equity ratio raises financial leverage concerns.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

MAS

Citigroup analyst Anthony Pettinari initiates coverage on Masco (NYSE:MAS) with a Neutral rating and a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:56 pm